Akèy › Lekemi selil B
Etid klinik pou Lekemi selil B ap rekrite nan Etazini
17 etid pou Lekemi selil B ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Houston, TX7 etid
- Dallas, TX5 etid
- Washington, DC5 etid
- Columbus, OH4 etid
- Portland, OR4 etid
- Clifton, NJ3 etid
- Charlotte, NC3 etid
- New York City, NY3 etid
- San Diego, CA3 etid
- Philadelphia, PA3 etid
- Louisville, KY3 etid
- Boston, MA3 etid
- Chicago, IL3 etid
- Edison, NJ3 etid
- Pittsburgh, PA3 etid
- Denver, CO3 etid
- Spokane, WA3 etid
Pa eta
- Colorado3 etid
- Florid3 etid
- Illinois4 etid
- Kalifòni7 etid
- Kansas3 etid
- Kentucky3 etid
- Maryland5 etid
- Massachusetts3 etid
- Minnesota3 etid
- New Jersey4 etid
- New York4 etid
- North Carolina5 etid
- Ohio7 etid
- Oregon4 etid
- Pennsylvania5 etid
- Texas12 etid
- Washington5 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT06542250CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
Ap rekriteFaz 1/2
Laj 3 a 39 · Tout sèks · Mizajou Sep 30, 2026 · NCT05442515Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Ap rekriteEtid obsèvasyon
Laj 18 a 110 · Tout sèks · Mizajou Sep 28, 2026 · NCT00923507Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
Ap rekriteFaz 4
Laj 18 a 130 · Tout sèks · Mizajou Sep 24, 2026 · NCT06651970Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT04728893Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)
Ap rekriteFaz 1
Jiska laj 75 · Tout sèks · Mizajou Sep 16, 2026 · NCT06345027A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT06564038Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
Ap rekriteFaz 3
Laj 18 a 18 · Tout sèks · Mizajou Sep 8, 2026 · NCT07509151Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)
Ap rekriteFaz 1
12 Months – 25 Years · Tout sèks · Mizajou Sep 4, 2026 · NCT05010564Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
Ap rekriteFaz 2
Laj 7 a 25 · Tout sèks · Mizajou Aug 19, 2026 · NCT05082519A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT05254743ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 11, 2026 · NCT07342478A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 31, 2026 · NCT06708897The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Ap rekriteFaz 1/2
Laj 12 a 95 · Tout sèks · Mizajou Apr 15, 2026 · NCT04329728A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Ap rekriteFaz 2
Laj 18 a 66 · Tout sèks · Mizajou Mar 17, 2026 · NCT06859424A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab
Ap rekriteEtid obsèvasyon
Laj 1 a 23 · Tout sèks · Mizajou Feb 25, 2026 · NCT07422337Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Jan 22, 2026 · NCT06357754Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.